Effects of Monoclonal Antibodies against Human Stathmin Combined with Paclitaxel on Proliferation of the QG-56 Human Lung Carcinoma Cell Line |
Yuan, Shao-Fei
(Cancer Center, Third Affiliated Hospital of Wenzhou Medical College)
Chen, Wen-Jun (Cancer Center, Third Affiliated Hospital of Wenzhou Medical College) Zhu, Lin-Jia (Cancer Center, Third Affiliated Hospital of Wenzhou Medical College) Zheng, Wei-E. (Cancer Center, Third Affiliated Hospital of Wenzhou Medical College) Chen, Hua (Cancer Center, Third Affiliated Hospital of Wenzhou Medical College) Xiong, Jian-Ping (Cancer Center, First Affiliated Hospital of Nanchang Universituy) |
1 | Alli E, Bash Balmla J, Yang JM, et a1 (2002). Effect ot stathmin on the sensitivity to antimierotubule drugs in human breast cancer. Cancer Res, 62, 6864-9. |
2 | Balachandran R, Welsh MJ, Day BW (2003). Ahered levels and regulation of stathmin in paclitaxel resistant ovarian cancer cells. Oncogene, 22, 8924-30. DOI |
3 | Flores ML, Castilla C, Avila R, et al (2011). Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat, 133, 917-28. |
4 | Hainsworth JD, Sosman JA, Spigel DR, et al (2004). Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Pro Am Soc Clin Oncol, 22, 382. |
5 | Hsieh SY, Huang SF, Yu MCto et al (2010). Stathmin overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog, 49, 476-87. |
6 | Jeon TY, Han ME, Lee YW, et al (2010). Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer, 102, 710-8. DOI |
7 | Le XF, Mao W, He G, et al (2011). The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst, 103, 1403- 22. DOI |
8 | Lin WC, Chen SC, Hu FC, et al (2009). Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology Epub, 74, 1264-9. DOI |
9 | Mistry SJ, Atweh GF (2002). Role of stathmin in the regulation of the mitotic spindle potential applications in cancer therapy. Mt Sinai J Med, 69, 299-304. |
10 | Rubin CI, Atweh GF (2004). The role of stathmin in the regulation of the cell cycle. J Cell Biochem, 93, 242-50. DOI ScienceOn |
11 | Segmnlan B, Holmfehh P, Morabito J, et a1 (2003). Autonomous and Phosphoeylation responsive microtubule regulating activities of the N-terminus of Opl8/stathnfin. J Cell Sci, 116, 97-205. |
12 | Su D, Smith SM, Preti M, et al (2009). Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer, 115, 2453-63. DOI |
13 | Xi W, Rui W, Fang L, et al (2009). Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol, 135, 837-46. DOI |
14 | Tuschl T, Borkhardt A(2002). Small interfering RNAs:a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv, 2, 158-67. DOI |
15 | Wang F, Wang LX, He W, et al (2010). Expression of stathmin in esophageal squamous cell carcinoma and its biological significance. Nan Fang Yi Ke Da Xue Xue Bao, 30, 1552- 7. |
16 | Wang F, Wang LX, He W, et al (2010). Up-regulation of stathmin induces growth arrest of esophageal squamous cell carcinoma EC9706 cell. Zhonghua Yi Xue Za Zhi, 90, 2140-4. |
17 | Zhou SW, Yan LH, Reb SX, et al (2008). Clinical study on the efficacy and safety of erlotinib in treatment of advanced non-small cell lung cancer. Tumor, 28, 780-5. |
18 | Yu J, Lee HJ, Hue K, et al (2010). The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal caicinomatosis mode. Invest New Drugs, 9, 1-5. |
19 | Zhang XT, Li LY, Wang SL, et al (2005). Treatment of nonsmall cell lung cancer with gefitinib. Chin J Tube Resp Dis, 28, 180-3. |
20 | Zheng P, Liu YX, Chen L, et al (2010). Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res, 9, 4897-905. DOI |